MBP and chronic myelogenous leukemia, BCR-ABL1 positive: Venetoclax has demonstrated preclinical efficacy against TKI-resistant CML cells and synergy with BCR-ABL TKI in eliminating leukemic stem cells in advanced CML In CML-MBP, dasatinib is effective as a single treatment; however, the venetoclax-TKI combination may be more effective than dasatinib alone.